A Phase 3 interventional study of DFD-03 and Placebo Comparator in Acne Vulgaris, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2021-03-01.
Sponsored by Dr. Reddy's Laboratories Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 67th largest by enrollment of the 354 interventional ones that give a count, is one of 23 that started in 2017, is one of 76 in phase 3, and was the 235th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 23 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 550 is above the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 354 interventional studies, 59 across the 19 observational. Of the 323 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
287 of 374 have an industry lead sponsor. The 10 most frequent:
Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.
Dr. Reddy's Laboratories Limited has 4 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
10 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07946250BrocShot IncA Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 374 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Enrollment of subjects with mild to moderate facial acne. Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at Baseline and Weeks 4, 8, and 12.
Safety assessments included the investigator's assessment of local cutaneous tolerance of the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching, vital signs, and adverse events (AEs).
Enrollment of subjects with mild to moderate facial acne. Subjects with acne lesions of any severity on the chest and/or back (including shoulders) were enrolled provided they had mild to moderate acne on the face. During the 12-week treatment period subjects used the study product twice daily. Subjects were instructed to treat the entire face (and chest and/or back including shoulders, if applicable).
Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at Baseline and Weeks 4, 8, and 12.
Safety assessments included the investigator's assessment of local cutaneous tolerance of the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching; assessed separately on the chest and/or back including shoulders (if applicable), vital signs (blood pressure and pulse rate), and adverse events (AEs). Urine pregnancy tests were performed at Baseline and at every visit through Week 12 for all female subjects. A physical examination was performed.
Main Inclusion Criteria:
Main Exclusion Criteria:
Treatment with the following products:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DFD-03 (0.1% tazarotene) Lotion
Drug: DFD-03
Vehicle (0% tazarotene) Lotion
Other: Placebo Comparator
DFD-03 Lotion
Also known as: Tazarotene 0.1% Lotion
Vehicle (tazarotene 0%) Lotion
Also known as: Vehicle
Absolute Change in the Inflammatory Lesion Counts on the Face
Change in inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using a two way analysis of covariance (ANCOVA) model
Time frame: Baseline to Week 12
Absolute Change in the Non-inflammatory Lesion Counts on the Face
Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the same ANCOVA model
Time frame: Baseline to Week 12
Proportion of Subjects With Treatment Success Based on IGA Score
IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline) - will be analyzed using the Cochran-Mantel-Haenszel (CMH) test for general association
Time frame: Baseline to Week 12
| Milestone | Active | Vehicle |
|---|---|---|
| Started | 277 | 273 |
| Completed | 219 | 228 |
| Not completed | 58 | 45 |
Change in inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using a two way analysis of covariance (ANCOVA) model
| Lesions | Active | Vehicle |
|---|---|---|
| Baseline | 30.1 ± 9.81 | 29.8 ± 9.13 |
| Week 12 | 15.4 ± 11.43 | 16.9 ± 11.78 |
Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the same ANCOVA model
| Lesions | Active | Vehicle |
|---|---|---|
| Baseline | 37.4 ± 14.71 | 36.6 ± 13.07 |
| Week 12 | 20.3 ± 13.88 | 22.1 ± 18.26 |
IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline) - will be analyzed using the Cochran-Mantel-Haenszel (CMH) test for general association
| Participants | Active | Vehicle |
|---|---|---|
| Proportion of Subjects With Treatment Success Based on IGA Score | 51 | 34 |
Collected over Adverse event data were collected from the time treatment was initiated until study product treatment was discontinued, except for spontaneously reported SAEs, which were to be reported up to 30 days after discontinuing study product use.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | 0/277 (0%) | 2/277 (0.7%) | 0/277 (0%) |
| Vehicle | 0/273 (0%) | 1/273 (0.4%) | 0/273 (0%) |
| Event | Active | Vehicle |
|---|---|---|
| Overian cyst rupturedReproductive system and breast disorders | 0/277 | 1/273 |
| AnxietyPsychiatric disorders | 1/277 | 0/273 |
| Polyps/EpithelioidNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/277 | 0/273 |
Intent to Treat (ITT) - The ITT population was the primary efficacy analysis data set and consisted of all subjects who were randomized and dispensed study medication.
| Age, Categorical(Participants) | Active | Vehicle | Total |
|---|---|---|---|
| <=18 years | 91 | 91 | 182 |
| Between 18 and 65 years | 186 | 182 | 368 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Active | Vehicle | Total |
|---|---|---|---|
| Mean | 21.2 ± 7.9 | 21.1 ± 8.0 | 21.2 ± 7.9 |
| Sex: Female, Male(Participants) | Active | Vehicle | Total |
|---|---|---|---|
| Female | 145 | 158 | 303 |
| Male | 132 | 115 | 247 |
| Ethnicity (NIH/OMB)(Participants) | Active | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 109 | 105 | 214 |
| Not Hispanic or Latino | 168 | 168 | 336 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 14 | 7 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 51 | 58 | 109 |
| White | 200 | 194 | 394 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 12 | 13 | 25 |
| Region of Enrollment(Participants) | Active | Vehicle | Total |
|---|---|---|---|
| United States | 277 | 273 | 550 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Apr 2018, 8 months.
Results were first posted in May 2020, 2 years 1 month after primary completion. A results delay was requested in Sep 2019.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 8 months is below that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Reddy's Laboratories Limited →